Taken together, the risk score calculated by weighted NRI and SIRI, combined with prognostic clinical characteristics, performed risk stratification better than the TNM stage for NSCLC patients treated with EGFR-TKI. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.